Drug Trial Radar · NCT05303701
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Jul 2027
Primary completion
Jan 2028
Study completion Jul 2031
Sponsor
- Lead sponsor
- Samsung Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of GV1001 administered subcutaneously in patients with moderate to severe Alzheimer's disease (AD).
Conditions
- Moderate to Severe Alzheimer's Disease
Interventions
GV1001 PlaceboDrug
0.9% normal saline
GV1001 1.12mgDrug
Lyophilized peptide from hTERT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in SIB(Severe Impairment Battery) score after GV1001 administration for 24 weeksTime frame: Baseline, Week 26
- CIBIC-plus (Clinician Interview-Based Impression of Change-Plus) score after GV1001 administration for 24 weeksTime frame: Baseline, Week 26
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.